Seq-Cabo: High-Dose Cabozantinib or Nivolumab Combination After Progression in Advanced RCC

By Tian Zhang, MD - Last Updated: July 8, 2024

Tian Zhang, MD, of UT Southwestern Medical Center, highlights the results of a phase 2 trial for sequential treatment of high dose cabozantinib or cabozantinib plus nivolumab after progression on cabozantinib monotherapy in advanced renal cell carcinoma.

View her other comments on Prostate Cancer Outcomes After Ga68-PSMA-PET Imaging.

Post Tags:ASCO 2024: Focus on Renal Cell Carcinoma

The Journey to a Personalized Vaccine: Dr. David Braun on Neoantigen mRNA Therapy in RCC

David Braun, MD, PhDAdvanced Renal Cell Carcinoma | March 24, 2025

Drs. Beckermann and Braun discuss the latter's Nature publication on a personalized neoantigen vaccine for RCC.

Impact of Insurance Status on Survival Outcomes in Metastatic RCC

Emily MenendezAdvanced Renal Cell Carcinoma | March 19, 2025

Patients with mRCC on Medicare have better survival rates compared with patients on Medicaid or with no insurance.

Ipi/Nivo Provides Better OS & FS in Older Adult Populations With mRCC

Emily MenendezAdvanced Renal Cell Carcinoma | February 25, 2025

The combination therapy provided similar survival rates and toxicity in an older patient population.

Extensive Necrosis as a Prognostic Indicator in mRCC Treated With Deferred Cytoreductive Nephrectomy After ICI Treatment

Daniel Joyce, MDRenal Cell Carcinoma | February 24, 2025

Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.

Treatment Characteristics, Survival Rates, and Costs of IO/IO and IO/TKI Therapies for mRCC

Emily MenendezAdvanced Renal Cell Carcinoma | January 29, 2025

First-line IO + IO therapy is linked to higher costs during the first three months of treatment.

Seq-Cabo: High-Dose Cabozantinib or Nivolumab Combination After Progression in Advanced RCC

Related Posts